logo
Galderma’sNemluvio(nemolizumab)DemonstratesLong-TermDiseaseControlinPrurigoNodularisuptoThreeYears
===2026/2/27 17:48:31===
Kwatra SG, et al. Prevalence of prurigo nodularis in the United States.JAAD Int. 2024;18:134-136. doi: 10.1016/j.jdin.2023.12.013.

Ständer S, et al. Prevalence of prurigo nodularis in the United States of America: A retrospective database analysis.JAAD Int. 2020;2:28-30. doi: 10.1016/j.jdin.2020.10.009.

Todberg T, et al. Treatment and Burden of Disease in a Cohort of Patients with Prurigo Nodularis: A Survey-based Study.Acta Derm Venereol. 2020;100(8):adv00119. doi: 10.2340/00015555-3471.

Kwatra SG. Breaking the Itch–Scratch Cycle in Prurigo Nodularis.N Engl J Med. 2020;382(8):757-758. doi: 10.1056/NEJMe1916733.

Aggarwal P, et al. Clinical characteristics and disease burden in prurigo nodularis.Clin Exp Dermatol. 2021;46(7):1277-1284. doi: 10.1111/ced.14722.








Contacts


For further information:

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@gal
=*=*=*=*=*=
当前为第11/12页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页